M&A Deal Summary |
|
|---|---|
| Date | 2021-07-19 |
| Target | EasyDNA |
| Sector | Life Science |
| Buyer(s) | Genetic Technologies |
| Sellers(s) | BelHealth Investment Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 4M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Genetic Technologies is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer have clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Genetic Technologies is based in Fitzroy, Australia.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Life Science) | 1 of 2 |
| Type (Add-on Acquisition) | 1 of 2 |
| State (California) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2021) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-07-14 |
AffinityDNA
East Sussex, United Kingdom AffinityDNA is a DNA Testing company with more than 15 years’ experience in the DNA business and established partnerships with some of the most highly accredited DNA testing laboratories in the world. AffinityDNA offers a number of lifestyle and health and wellbeing tests, and animal testing relating to allergies and tolerances. AffinityDNA is based in East Sussex, United Kingdom. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2011 |
| PE ASSETS | 500M USD |
| Size | Middle-Market |
| Type | Sector Focused |
BelHealth Investment Partners LLC is private equity firm focused on mid-sized healthcare companies. The Firm looks to invest $20 to $50 million per transaction and specifically targets healthcare services, healthcare products, healthcare distribution, and healthcare IT. BelHealth prefers companies with recurring revenue, high margins, diverse customers, low regulatory oversight, and modest technology risk. Prospective companies are typically profitable with at least $20-$100 million of enterprise value, $10-$100 million of revenue and $2-$10 million of EBITDA. BelHealth was formed in 2011 and is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 7 |
| Sector (Life Science) | 2 of 2 |
| Type (Add-on Acquisition) | 4 of 4 |
| State (California) | 2 of 2 |
| Country (United States) | 6 of 7 |
| Year (2021) | 2 of 3 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-01 |
Care Advantage
Richmond, Virginia, United States Care Advantage is a provider of home healthcare and related services in Virginia. The Company specializes in “one-on-one” quality nursing care in the home for both “unskilled care” and “skilled care” patients. Care Advantage was founded in 1988 and is based in Richmond, Virginia. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-22 |
AHSG
Edmond, Oklahoma, United States AHSG is a national and diversified healthcare staffing platform, serving thousands of endpoints across health systems, hospitals, and outpatient clinics in all 50 states. AHSG’s seven divisions span across high growth and resilient segments of healthcare staffing including nursing, allied health, pharmacy, interim leadership, dialysis, non-clinical and technology. AHSG was founded in 2010 and is based in Edmond, Oklahoma. |
Sell | - |
